<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">33065300</PMID><DateCompleted><Year>2021</Year><Month>11</Month><Day>25</Day></DateCompleted><DateRevised><Year>2021</Year><Month>11</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1877-0665</ISSN><JournalIssue CitedMedium="Internet"><Volume>64</Volume><Issue>5</Issue><PubDate><Year>2021</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Annals of physical and rehabilitation medicine</Title><ISOAbbreviation>Ann Phys Rehabil Med</ISOAbbreviation></Journal><ArticleTitle>Anosognosia in amyotrophic lateral sclerosis: A cross-sectional study of 85 individuals and their relatives.</ArticleTitle><Pagination><StartPage>101440</StartPage><MedlinePgn>101440</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.rehab.2020.08.004</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1877-0657(20)30171-8</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Amyotrophic lateral sclerosis (ALS) has long been considered a pure motor neurodegenerative disease. However, now, extra-motor manifestations such as cognitive-behavioral disorders are considered not rare and are even a severity factor of the disease. Experiencing anosognosia (i.e., the inability to recognize neurological symptoms) might affect care and treatment compliance in ALS. Regardless, this pivotal feature has been little investigated.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">By comparing patients' and caregivers' reports, we analysed whether patients with ALS would experience a lack of awareness about their executive disorders and their apathy symptoms.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">From the ALS reference center in Paris, we included 85 patients (47 men, mean [SD] age 60.5 [12] years and ALS-Functional Rating Scale-revised score 8 to 46) and their primary family caregivers who all completed the Dysexecutive Questionnaire (DEX) and the Apathy Evaluation Scale (AES). Overall scores and answers were compared by agreement/disagreement statistical methods.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Caregivers reported higher levels of cognitive-behavioral disorders than did patients, but reports matched when cognitive-behavioral disorders were absent or mild. With published DEX and AES cutoffs, 32% and 51% of patients had executive disorders and apathy, respectively. In these patients with significant impairment, Bland-Altman plots (i.e., visual display agreement that represents the difference between the patient's and caregiver's scores as a function of their average) showed a strong discrepancy between joint reports: patients underestimated their symptoms by a mean bias of -6.81 DEX points (95% confidence interval -11.88, -1.75) and -8.85 AES points (95% confidence interval -11.72, -5.98). We found no clear relationship between bulbar or spinal ALS subtypes and anosognosia.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">ALS patients with a cognitive-behavioral phenotype show anosognosia by a mismatch between self and proxy reports, which warrants further investigation in neuroimaging. Systematic longitudinal screening of anosognosia is needed to propose targeted psychoeducation in patient-caregiver dyads showing disagreement.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 Elsevier Masson SAS. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Salah</LastName><ForeName>Amina Ben</ForeName><Initials>AB</Initials><AffiliationInfo><Affiliation>Department of Physical Rehabilitation Medicine, Piti&#xe9;-Salp&#xea;tri&#xe8;re hospital (AP-HP) and GRC 24 (Sorbonne Universit&#xe9;), 47, boulevard de l'H&#xf4;pital, 75013 Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pradat</LastName><ForeName>Pierre-Fran&#xe7;ois</ForeName><Initials>PF</Initials><AffiliationInfo><Affiliation>Laboratoire d'imagerie biom&#xe9;dicale (LIB), Sorbonne universit&#xe9;, Paris, France; Department of Neurology and Reference ALS Center, Piti&#xe9;-Salp&#xea;tri&#xe8;re Hospital (AP-HP), Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Villain</LastName><ForeName>Marie</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Physical Rehabilitation Medicine, Piti&#xe9;-Salp&#xea;tri&#xe8;re hospital (AP-HP) and GRC 24 (Sorbonne Universit&#xe9;), 47, boulevard de l'H&#xf4;pital, 75013 Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Balcerac</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Physical Rehabilitation Medicine, Piti&#xe9;-Salp&#xea;tri&#xe8;re hospital (AP-HP) and GRC 24 (Sorbonne Universit&#xe9;), 47, boulevard de l'H&#xf4;pital, 75013 Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pradat-Diehl</LastName><ForeName>Pascale</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Physical Rehabilitation Medicine, Piti&#xe9;-Salp&#xea;tri&#xe8;re hospital (AP-HP) and GRC 24 (Sorbonne Universit&#xe9;), 47, boulevard de l'H&#xf4;pital, 75013 Paris, France; Laboratoire d'imagerie biom&#xe9;dicale (LIB), Sorbonne universit&#xe9;, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salachas</LastName><ForeName>Francois</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Neurology and Reference ALS Center, Piti&#xe9;-Salp&#xea;tri&#xe8;re Hospital (AP-HP), Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lacomblez</LastName><ForeName>Lucette</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neurology and Reference ALS Center, Piti&#xe9;-Salp&#xea;tri&#xe8;re Hospital (AP-HP), Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bayen</LastName><ForeName>El&#xe9;onore</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Physical Rehabilitation Medicine, Piti&#xe9;-Salp&#xea;tri&#xe8;re hospital (AP-HP) and GRC 24 (Sorbonne Universit&#xe9;), 47, boulevard de l'H&#xf4;pital, 75013 Paris, France; Laboratoire d'imagerie biom&#xe9;dicale (LIB), Sorbonne universit&#xe9;, Paris, France; Global Brain Health Institute, Memory and Aging Center, University of California San Francisco, San Francisco, USA. Electronic address: Eleonore.bayen@gbhi.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>09</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Ann Phys Rehabil Med</MedlineTA><NlmUniqueID>101502773</NlmUniqueID><ISSNLinking>1877-0657</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000377" MajorTopicYN="Y">Agnosia</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057565" MajorTopicYN="Y">Apathy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Anosognosia</Keyword><Keyword MajorTopicYN="N">Apathy</Keyword><Keyword MajorTopicYN="N">Dysexecutive disorders</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>3</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>8</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>8</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>10</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>10</Month><Day>16</Day><Hour>20</Hour><Minute>11</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33065300</ArticleId><ArticleId IdType="doi">10.1016/j.rehab.2020.08.004</ArticleId><ArticleId IdType="pii">S1877-0657(20)30171-8</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>